top of page

Unlocking Hope for Multiple Sclerosis Patients

Multiple sclerosis (MS) is a complex and challenging neurodegenerative disease, affecting millions worldwide. At AdRegeneer, we stand at the forefront of medical innovation, driven by a determined commitment to transforming the lives of those living with MS. Our clinical trials offer a beacon of hope to patients and their families, aiming to provide effective solutions where current treatments fall short. By supporting our mission, you become a vital partner in our quest to rewrite the story of multiple sclerosis, offering the promise of regaining what's been lost.

Clinical trial, HDAC2 activator pipeline for drug development

Support Our Ongoing Clinical Trials

Clinical trials are a cornerstone of our research, and your support can drive transformative change. By joining us in this endeavor, you're helping rewrite the future of nervous system regeneration and offering hope to countless individuals.

Phase I Clinical Trial for Transdermal Patches:

In Phase I, we're testing innovative transdermal patches to deliver our regenerative therapy. Your support can help us evaluate safety and effectiveness, paving the way for improved treatments.

Phase II Clinical Trial for Remyelination:

We're on the verge of launching Phase II, focusing on the efficiency of our remyelination-specific formulation in repairing lesions of multiple sclerosis patients. Your support can help us initiate this groundbreaking work and prepare for the trials.

bottom of page